📋 Key Information Summary
- Deprescribing analgesics is the planned, supervised process of dose reduction or cessation to minimise medication-related harm while maintaining adequate pain control and quality of life.
- Always establish a patient-centred treatment goal before tapering — agree on a realistic pain/function target rather than "zero pain".
- Opioid tapering should proceed at 5–10% of the original dose per week for low-risk patients; 10–25% every 2–4 weeks is acceptable if the patient is stable; very slow tapers (≤10% per month) are recommended for high-dose or long-term use (≥12 months).
- Abrupt opioid cessation is contraindicated except in life-threatening situations — it precipitates withdrawal and increases the risk of illicit opioid use and overdose.
- Long-acting opioids should be converted to short-acting formulations before tapering to allow finer dose titration.
- Adjuvant analgesics (gabapentinoids, TCAs, SNRIs) also require gradual tapering; gabapentinoids should be reduced by 10–25% every 1–2 weeks; abrupt cessation of pregabalin or gabapentin can cause seizures.
- Benzodiazepines co-prescribed with opioids significantly increase the risk of fatal overdose — deprescribing benzodiazepines should be prioritised alongside or before opioid tapering.
- Benzodiazepine reduction of 5–10% every 1–2 weeks (or 25% dose reduction with 2–3 week stabilisation intervals) reduces withdrawal severity; longer half-life agents (diazepam) can be substituted to ease tapering of short-acting agents.
- Monitor for withdrawal symptoms using the Clinical Opiate Withdrawal Scale (COWS) for opioids and the Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) or CIWA-Ar adapted for benzodiazepines.
- Non-pharmacological strategies — cognitive behavioural therapy (CBT), graded exercise, physiotherapy, and pain neuroscience education — must be integrated before and during any taper.
- Aboriginal and Torres Strait Islander peoples may face unique barriers including limited access to specialist pain services, culturally inappropriate care, and distrust of mainstream health systems — a culturally safe, community-led approach is essential.
- Patients on ≥50 mg morphine equivalent daily dose (MEDD) or those with concurrent benzodiazepine use, substance-use history, or mental health comorbidities require specialist input and close monitoring.
Introduction & Australian Epidemiology
Chronic non-cancer pain affects approximately 3.24 million Australians and is a leading cause of disability, lost productivity, and healthcare utilisation. Opioid dispensing rates in Australia remain among the highest in the OECD, with over 15 million opioid prescriptions dispensed annually through the Pharmaceutical Benefits Scheme (PBS). Long-term opioid therapy (LTOT), defined as use for ≥90 days, is associated with dose-dependent risks of overdose, falls, fractures, constipation, hormonal disturbance, immunosuppression, and paradoxical opioid-induced hyperalgesia.
Deprescribing is the planned, supervised process of dose reduction or cessation of medications whose current or potential harms outweigh ongoing benefits. In the context of analgesics, deprescribing does not mean abandoning pain management — rather, it involves transitioning to safer, multimodal strategies while withdrawing agents that are no longer providing meaningful functional benefit or that carry unacceptable risk.
The Australian Commission on Safety and Quality in Health Care (ACSQHC) has identified medication-related harm as a national priority. Opioid-related hospitalisations have increased by 25% over the past decade, and opioid-related deaths exceed 1,000 annually. Benzodiazepines and gabapentinoids contribute to a substantial proportion of polypharmacy-related adverse events, particularly in the elderly and those on combination sedative therapy.
This guideline provides a structured, evidence-based framework for deprescribing opioid analgesics, adjuvant agents (gabapentinoids, tricyclic antidepressants, SNRIs), and benzodiazepines in the Australian primary care and specialist setting. It emphasises shared decision-making, gradual tapering, withdrawal monitoring, and integration of non-pharmacological pain management.
Key principle: Deprescribing is not failure of prior treatment. It is an active, therapeutic intervention that tests ongoing need and reduces cumulative medication harm. Frame it positively with patients: "We are finding the lowest dose that works for you."
Opioid Tapering
When to Consider Opioid Deprescribing
- Pain has not improved by ≥30% on validated scales (e.g. Brief Pain Inventory, NRS) or function has not meaningfully improved despite ≥4 weeks of stable dose.
- Dose escalation continues without functional gain (opioid dose spiral).
- Medication-related adverse effects are impacting quality of life (constipation, sedation, hormonal dysfunction, falls).
- Patient expresses a desire to reduce or stop opioids.
- Dose exceeds 50 mg MEDD without clear justification — risk of overdose increases substantially above this threshold.
- Concurrent benzodiazepine or gabapentinoid co-prescription raises the risk of fatal respiratory depression.
- Signs of opioid use disorder are emerging (loss of control, escalating requests, use of non-prescribed opioids).
Tapering Schedules
The pace of tapering must be individualised based on duration of use, current dose, co-prescribed sedatives, patient preference, and psychosocial supports. The following framework is recommended:
| Risk Profile | Taper Rate | Monitoring Interval | Setting |
|---|---|---|---|
| Low risk — short duration (<6 months), low dose (<30 mg MEDD), no SUD history, no concurrent benzodiazepines | 10–25% dose reduction every 2–4 weeks | Every 2–4 weeks | GP-led |
| Moderate risk — 6–12 months use, 30–90 mg MEDD, stable mental health | 5–10% dose reduction every 1–2 weeks | Every 1–2 weeks initially, then monthly | GP with pain team support |
| High risk — >12 months use, ≥90 mg MEDD, concurrent benzodiazepines, SUD history, significant mental health comorbidity | 10% dose reduction per month (or slower) | Weekly initially, then fortnightly | Specialist pain service / addiction medicine |
Step-by-Step Opioid Taper Protocol
1
Assess & Prepare
Conduct a comprehensive pain review. Validate pain with empathy. Set shared goals (function, not zero pain). Screen for SUD (AUDIT-C, DAST-10), mental health (PHQ-9, GAD-7), and social supports. Engage allied health (physiotherapy, psychology). Establish a taper agreement.
2
Formulate a Taper Plan
Convert to a single long-acting opioid if possible, OR convert to short-acting formulation for finer dose adjustments. Reduce total MEDD by 5–25% as per risk category. Consider buprenorphine conversion for high-dose opioid tapers (see below). Schedule follow-up appointments in advance.
3
Initiate & Monitor
Begin taper. Provide a withdrawal symptom diary. Use COWS at each visit. Offer non-pharmacological supports. Adjust pace — if withdrawal is intolerable, hold at current dose for 2–4 weeks before resuming. Never reverse an opioid taper unless safety is at risk.
4
Final Steps & Cessation
When dose reaches the equivalent of ≤10 mg oral morphine per day, consider discontinuing entirely. Provide a naloxone kit (PBS-listed). Schedule a post-cessation review at 2 and 6 weeks. Continue non-pharmacological pain strategies indefinitely.
Role of Buprenorphine in Opioid Tapering
Buprenorphine (partial μ-agonist) is increasingly used as a "bridge" medication to facilitate opioid tapering, particularly in patients on high-dose full agonists or those with features of opioid dependence. Buprenorphine-naloxone (Suboxone®) can be initiated under GP authority (with appropriate training) or via specialist addiction medicine services.
Buprenorphine-naloxone
Suboxone® Film · Partial μ-agonist / antagonist
Adult dose (tapering)
Initiate 4–8 mg SL once daily; titrate to 8–16 mg SL daily; taper by 2 mg every 1–2 weeks
Paediatric dose
Not routinely recommended for paediatric tapering; specialist-only
Renal adjustment
No adjustment required; caution in severe renal impairment
Hepatic adjustment
Avoid in severe hepatic impairment (Child-Pugh C); dose reduction in moderate impairment
PBS status
⚠ Authority Required
Never abruptly cease opioids in a patient who has been on them for >2 weeks. Abrupt cessation causes severe withdrawal (anxiety, diaphoresis, myalgia, nausea, diarrhoea, tachycardia), increases the risk of illicit opioid use and fatal overdose, and erodes therapeutic trust.
Opioid Medications — Deprescribing Notes
Oxycodone
OxyNorm® / OxyContin® · Full μ-agonist
Taper approach
Convert controlled-release (OxyContin) to immediate-release (OxyNorm) for dose flexibility; reduce by 10–25% every 1–2 weeks as tolerated
Renal adjustment
Active metabolite (oxymorphone) accumulates in renal impairment — increase taper interval or convert to morphine or fentanyl
PBS status
⚠ Authority Required (opioid pack program)
Tapentadol
Palexia® · μ-agonist / NRI
Taper approach
Reduce by 50 mg every 1–2 weeks (controlled-release); minimum available dose is 50 mg SR; discontinue once at 50 mg daily for 1 week
Special note
Serotonin syndrome risk if co-prescribed with SSRIs/SNRIs/MAOIs — assess before taper
PBS status
⚠ Authority Required
Tramadol
Tramal® · μ-agonist / SNRI-like
Taper approach
Reduce by 50 mg every 3–7 days; watch for both opioid withdrawal AND SNRI-like discontinuation symptoms (dizziness, paraesthesia, irritability, brain zaps)
Seizure risk
Lowered seizure threshold — taper gradually; avoid abrupt cessation
PBS status
✔ PBS General Benefit
Adjuvant Tapering
Adjuvant analgesics are widely used in chronic pain management. They also carry significant withdrawal and discontinuation risks that are frequently under-recognised. A structured approach to deprescribing adjuvants is as important as opioid tapering.
Gabapentinoids (Pregabalin, Gabapentin)
Gabapentinoids are among the most commonly prescribed analgesic adjuvants in Australia. Pregabalin (Lyrica®) and gabapentin (Neurontin®) act on the α2δ subunit of voltage-gated calcium channels. They are effective for neuropathic pain and fibromyalgia but carry risks of sedation, dizziness, weight gain, peripheral oedema, and misuse potential. Abrupt cessation — particularly of pregabalin — can precipitate seizures, insomnia, anxiety, diaphoresis, and rebound pain.
Do not abruptly stop gabapentinoids. Abrupt discontinuation of pregabalin or gabapentin can cause seizures, even in patients without a history of epilepsy. This risk is dose-dependent and higher at doses >300 mg/day of pregabalin or >1200 mg/day of gabapentin.
| Medication | Taper Strategy | Timeline | Key Risks |
|---|---|---|---|
| Pregabalin (Lyrica®) | Reduce by 25–50 mg every 1–2 weeks. At ≤75 mg/day, reduce by 25 mg per week. | 4–12 weeks depending on starting dose | Seizures, insomnia, rebound anxiety, rebound pain |
| Gabapentin (Neurontin®) | Reduce by 100–300 mg every 1–2 weeks. At ≤300 mg/day, reduce by 100 mg per week. | 4–16 weeks depending on starting dose | Seizures (especially if doses >1200 mg/day), anxiety, insomnia |
Pregabalin
Lyrica® · α2δ ligand
Adult taper
Reduce by 25–50 mg every 1–2 weeks; final step 25 mg/day → cease
Renal adjustment
GFR 30–59: max 150 mg/day (initial); GFR 15–29: max 75 mg/day; Haemodialysis: supplemental dose post-dialysis — taper accordingly
PBS status
⚠ Authority Required
Gabapentin
Neurontin® · α2δ ligand
Adult taper
Reduce by 100–300 mg every 1–2 weeks; final step 100 mg/day → cease
Renal adjustment
GFR 30–59: max 300 mg BD; GFR 15–29: max 300 mg daily; GFR <15: 300 mg every other day — taper accordingly
PBS status
✔ PBS General Benefit
Tricyclic Antidepressants (TCAs)
Amitriptyline (Endep®) and nortriptyline are commonly used for neuropathic pain, migraine prophylaxis, and chronic musculoskeletal pain at low doses (10–75 mg nocte). Even at low doses, abrupt cessation can cause cholinergic rebound (nausea, sweating, headache, malaise, anxiety) and sleep disturbance.
Amitriptyline
Endep® · TCA
Adult taper
Reduce by 10 mg every 1–2 weeks. At 10 mg/day, reduce to 5 mg for 1 week then cease, or reduce frequency to alternate nights then cease.
Special note
Cardiac monitoring (ECG) is recommended if patient was on doses >100 mg/day or has cardiac risk factors; watch for anticholinergic rebound
PBS status
✔ PBS General Benefit
SNRIs (Duloxetine, Venlafaxine)
Duloxetine (Cymbalta®) is PBS-listed for neuropathic pain and is widely used. Venlafaxine (Efexor®) has evidence for neuropathic pain at higher doses (≥150 mg). SNRI discontinuation syndrome is well-characterised and can be severe — particularly with venlafaxine, which has a short half-life. Symptoms include dizziness, "brain zaps" (electric shock sensations), irritability, nausea, insomnia, and mood disturbance.
Duloxetine
Cymbalta® · SNRI
Adult taper
Reduce by 30 mg every 1–2 weeks. At 30 mg/day, reduce to 20 mg (if available) or open capsule and reduce bead count, then cease after 1 week at minimum dose.
Special note
If discontinuation symptoms are intolerable, switch to fluoxetine 20 mg (long half-life) and taper fluoxetine instead
PBS status
⚠ Authority Required
Venlafaxine
Efexor-XR® · SNRI
Adult taper
Reduce by 37.5 mg every 1–2 weeks. At 37.5 mg/day, open capsule and reduce bead count over 2–4 weeks, or switch to fluoxetine cross-taper.
Special note
Highest risk of discontinuation syndrome among antidepressants — counsel patients proactively
PBS status
✔ PBS General Benefit
Other Adjuvants
| Medication Class | Common Agents | Taper Approach | Withdrawal Risk |
|---|---|---|---|
| Muscle relaxants | Cyclobenzaprine, baclofen | Baclofen: reduce by 5–10 mg every 3–7 days (risk of seizures and rebound spasticity); Cyclobenzaprine: reduce gradually over 1–2 weeks | Seizures (baclofen), rebound spasticity, hallucinations (baclofen at high doses) |
| Corticosteroids | Prednisolone | If >3 weeks use: taper by 5 mg every 1–2 weeks (≤20 mg) then by 2.5 mg every 1–2 weeks; physiological replacement may be needed | Adrenal insufficiency, arthralgia, fatigue, mood disturbance |
| Alpha-2 delta ligands (topical) | Lidocaine patches 5% | Can be discontinued without taper; no withdrawal risk | None |
Benzodiazepines
Benzodiazepines are frequently co-prescribed with opioids for chronic pain, anxiety, insomnia, or muscle spasm. The combination of opioids and benzodiazepines is the most dangerous common polypharmacy combination in pain medicine — it increases the risk of fatal respiratory depression by up to 10-fold. Australian data show that benzodiazepines are implicated in approximately 60% of opioid-related deaths.
Priority action: The RACGP, TGA, and ACSQHC recommend that benzodiazepine deprescribing should be prioritised alongside or before opioid tapering in patients on concurrent therapy. The combination is uniquely lethal. If only one agent can be tapered at a time, consider deprescribing the benzodiazepine first to reduce the overdose risk of the remaining opioid.
Indications for Benzodiazepine Deprescribing
- Co-prescription with opioids (absolute indication for deprescribing)
- Use for ≥4 weeks for any indication
- Increasing dose without clinical benefit
- Adverse effects: falls, cognitive impairment, daytime sedation, road traffic risk
- Patient-expressed desire to stop
- Age ≥65 years — falls risk and cognitive effects are amplified (Beers criteria agent)
Tapering Strategy
The key principle is gradual, patient-led dose reduction with psychological support. Evidence supports both gradual dose reduction over weeks to months and symptom-titrated tapering.
1
Stabilise
If on multiple benzodiazepines, convert to a single agent — preferably diazepam (long half-life, available in small dose increments). Use the Ashton equivalence table for conversion. Stabilise on the diazepam equivalent for 1–2 weeks before starting the taper.
2
Taper
Reduce by approximately 5–10% of the current dose every 1–2 weeks. An alternative schedule: reduce by 25% of the original dose, stabilise for 2–3 weeks, then reduce by another 25% of the original dose, and so on. Slower is better for patients on high doses, long duration, or with concurrent mental health conditions.
3
Final Cessation
The last 25% of the dose is often the hardest. At ≤2 mg diazepam daily, reduce by 0.5 mg every 1–2 weeks. Many patients benefit from alternate-day dosing before full cessation. Schedule a post-cessation review at 2 weeks and 6 weeks.
Benzodiazepine Equivalence Table (to Diazepam)
| Agent | Approximate Equivalent Dose | Half-life | Taper Ease |
|---|---|---|---|
| Diazepam | 10 mg (reference) | 20–100 hours (active metabolites) | Easiest — long half-life acts as self-taper |
| Alprazolam (Xanax®) | 0.5 mg | 6–12 hours | Difficult — short half-life, high potency; convert to diazepam first |
| Clonazepam (Rivotril®) | 0.5 mg | 18–50 hours | Moderate — can taper directly or convert to diazepam |
| Lorazepam (Ativan®) | 1 mg | 10–20 hours | Moderate — convert to diazepam for smoother taper |
| Oxazepam (Serepax®) | 20 mg | 4–15 hours | Moderate — short half-life, no active metabolites; safe in elderly and hepatic impairment |
| Temazepam (Temaze® / Normison®) | 20 mg | 5–13 hours | Moderate — commonly used for insomnia; convert to diazepam for taper |
| Nitrazepam (Mogadon®) | 10 mg | 16–48 hours | Moderate — long-acting; can taper directly |
Pharmacological Aids for Benzodiazepine Tapering
- Psychological support: CBT and graded exposure for insomnia and anxiety are strongly recommended and are PBS-subsidised under GP Mental Health Treatment Plans (up to 10 sessions per calendar year, item 80110/80111).
- Fluoxetine bridge: For patients discontinuing SNRIs/SSRIs concurrently, switching to fluoxetine (long half-life ~4–6 days) and then tapering fluoxetine can smooth discontinuation.
- Clonidine: May assist with autonomic symptoms of withdrawal (off-label); 50–100 μg PO TDS as needed. Not PBS-listed for this indication.
- Anticonvulsants: Carbamazepine has some evidence for managing benzodiazepine withdrawal symptoms but is not standard practice.
Patient safety: Provide a written taper plan, schedule regular reviews (weekly initially), counsel about withdrawal symptoms that may appear 1–3 days after dose reduction, and ensure access to crisis support. Reassure patients that withdrawal symptoms are temporary and expected.
Monitoring Withdrawal
Systematic monitoring is essential during any deprescribing process. Withdrawal symptoms can be subtle and insidious, and failure to monitor can result in patient distress, premature discontinuation of the taper, or illicit substance use to self-manage symptoms.
Clinical Opiate Withdrawal Scale (COWS)
The COWS is the standard validated tool for assessing opioid withdrawal severity. It should be administered at each visit during the taper. A COWS score of 5–12 indicates mild withdrawal; 13–24 moderate; 25–36 moderately severe; >37 severe withdrawal.
| COWS Score | Severity | Action |
|---|---|---|
| 5–12 | Mild withdrawal | Continue taper; offer reassurance, paracetamol, NSAIDs; review at next scheduled visit |
| 13–24 | Moderate withdrawal | Hold current dose for 1–2 weeks; symptom manage (loperamide, ondansetron, clonidine); review in 1 week |
| 25–36 | Moderately severe | Increase dose back to last tolerated dose; slow taper rate; consider specialist referral; review within 48–72 hours |
| >37 | Severe withdrawal | Emergency management; consider buprenorphine induction or methadone stabilisation; refer to addiction medicine |
Opioid Withdrawal Symptoms — Recognition Guide
Early / Mild
Autonomic & Mood
Anxiety, restlessness, lacrimation, rhinorrhoea, yawning, diaphoresis, piloerection, mild myalgia, insomnia
Typically appears: 12–24 hours after last dose (short-acting); 36–72 hours (long-acting)
Moderate
Gastrointestinal & Musculoskeletal
Nausea, vomiting, diarrhoea, abdominal cramping, significant myalgia, arthralgia, tachycardia, hypertension, dilated pupils
Typically appears: 24–48 hours; peaks at 3–5 days
Severe / Dangerous
Cardiovascular & Behavioural
Severe dehydration, electrolyte derangement, hypertensive crisis (rare), profound distress, suicidal ideation, relapse to illicit opioids
Requires urgent medical review and possible inpatient management
Benzodiazepine Withdrawal — Monitoring
Benzodiazepine withdrawal symptoms can be delayed (1–7 days after dose reduction for short-acting agents; up to 2–3 weeks for long-acting agents) and can include perceptual disturbances (hypersensitivity to light/sound, depersonalisation, derealisation) that mimic psychiatric illness. Use the Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) or a structured clinical assessment at each visit.
Monitoring Timeline
Week 1–2
Weekly review. COWS for opioids. Vital signs. Assess mood, sleep, function. Urine drug screen if clinically indicated. Naloxone kit provision.
Week 3–8
Fortnightly review. Continue COWS. Brief Pain Inventory (BPI) functional assessment. PHQ-9 / GAD-7. Review allied health engagement. Adjust taper pace if needed.
Month 2–6
Monthly review. Ongoing functional assessment. Support non-pharmacological strategies. Address any new concerns. Consider specialist referral if plateau.
Post-cessation
Review at 2 weeks and 6 weeks post-cessation. Monitor for protracted withdrawal (PAWS) — can persist 6–18 months. Maintain non-pharmacological strategies. Relapse prevention planning.
Symptomatic Management During Tapering
Loperamide
Imodium® · Peripheral μ-agonist
Adult dose
4 mg initially, then 2 mg after each loose stool (max 16 mg/day)
Indication
Opioid withdrawal diarrhoea
PBS status
✔ PBS General Benefit
Ondansetron
Zofran® · 5-HT3 antagonist
Adult dose
4–8 mg PO/ODT/IV every 8 hours PRN
Indication
Opioid withdrawal nausea/vomiting
PBS status
✔ PBS General Benefit (oral); ⚠ Authority Required (IV)
Paracetamol
Panadol® · Non-opioid analgesic
Adult dose
1 g PO every 4–6 hours (max 4 g/day); reduce to 2 g/day if hepatic impairment or weight <50 kg
Indication
Rebound pain, myalgia, arthralgia during taper
PBS status
✔ PBS General Benefit
Clonidine
Catapres® · α2-agonist
Adult dose
50–100 μg PO every 8 hours PRN (off-label for withdrawal symptoms)
Indication
Autonomic symptoms — tachycardia, hypertension, diaphoresis, anxiety during opioid or benzodiazepine withdrawal
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit (hypertension indication; off-label for withdrawal)
Naloxone Provision
Naloxone (Nyxoid®) nasal spray should be offered to all patients who are tapering opioids, particularly those on ≥50 mg MEDD, those with a history of substance use disorder, or those co-using benzodiazepines. Naloxone is now PBS-listed as an Authority Required item for patients at risk of opioid overdose. Prescribe 2 doses and ensure the patient and/or a support person is trained in its use.
Naloxone nasal spray
Nyxoid® · Opioid antagonist
Dose
1.8 mg (1 spray) into one nostril; repeat with second device in 2–3 minutes if no response
Duration of action
30–90 minutes — shorter than most opioids; monitor for re-sedation and re-dose if needed
PBS status
⚠ Authority Required
Non-Pharmacological Pain Strategies
Deprescribing must be embedded within a multimodal pain management plan. Initiating or optimising non-pharmacological strategies before starting a taper improves outcomes, reduces withdrawal distress, and provides the patient with alternative coping mechanisms.
1
Pain Neuroscience Education
Explain the biopsychosocial model of chronic pain. Help patients understand central sensitisation, fear-avoidance, and the difference between hurt and harm. Resources: Explain Pain (Butler & Moseley), Pain Australia (painaustralia.org.au).
2
Graded Physical Activity
Physiotherapy-led graded exercise therapy (GET). Start at the patient's current capacity and increase by 10% per week. Avoid boom-bust cycles. Refer to a pain-specialised physiotherapist where available.
3
Psychological Therapies
CBT for pain, acceptance and commitment therapy (ACT), and mindfulness-based stress reduction (MBSR). Available under GP Mental Health Treatment Plans (Medicare items 80110–80170; up to 10 sessions/year). Interdisciplinary pain programs provide integrated care.
4
Self-Management Support
Flare-up action plans. Sleep hygiene strategies. Peer support groups. Online programs: MyPainHub (WA), MindSpot chronic pain course. Occupational therapy for activity pacing and return-to-work planning.
Special Populations
Pregnancy
Opioids — Neonatal abstinence syndrome (NAS) risk with chronic opioid use; do NOT abruptly cease in pregnancy (risk of fetal distress, miscarriage); taper under specialist obstetric and pain medicine supervision.
Benzodiazepines — Contraindicated; associated with neonatal floppy infant syndrome, cleft palate (first trimester). Taper before conception if possible; if unplanned pregnancy, slow taper with specialist oversight.
Gabapentinoids — Category B3 (TGA); limited data; avoid if possible; specialist decision-making required.
Paracetamol — Safe in all trimesters at standard doses.
All deprescribing in pregnancy requires shared decision-making with obstetrics, pain medicine, and the patient. Frame as harm minimisation, not withdrawal.
Paediatrics
Opioids — Paediatric opioid tapering is specialist-led. Dose reductions of 10–20% every 3–7 days with symptom monitoring (WAT-1 scale for neonates; adapted COWS for children).
Benzodiazepines — Neonatal benzodiazepine tapering after iatrogenic exposure requires NICU/PICU supervision. Use diazepam 0.1–0.2 mg/kg/dose every 6–8 hours and reduce by 10–20% every 3–5 days.
Gabapentinoids — Limited paediatric evidence; specialist-only indication.
Paediatric deprescribing should always involve a multidisciplinary team including paediatric pain specialists, child psychologists, and family support services.
Elderly (≥65 years)
All analgesics — Increased sensitivity to opioids, benzodiazepines, and gabapentinoids due to altered pharmacokinetics (reduced renal clearance, increased fat distribution, reduced hepatic metabolism).
Falls risk — Opioids and benzodiazepines are independent risk factors for falls and fractures in older adults. Deprescribing may be indicated even at "low" doses if falls are occurring.
Cognitive effects — Benzodiazepines and opioids accelerate cognitive decline; deprescribing may improve cognition. Use MMSE/MoCA to baseline and track.
Taper pace — Use the slowest recommended taper rate; older adults are more susceptible to withdrawal symptoms and rebound effects.
The Beers Criteria (American Geriatrics Society) lists benzodiazepines, long-acting opioids (tramadol, morphine MR), and TCAs as potentially inappropriate medications in older adults.
Renal Impairment
Morphine — Active metabolite (M6G) accumulates in renal impairment, causing prolonged sedation and respiratory depression. Convert to fentanyl or buprenorphine before tapering if GFR <30 mL/min.
Gabapentin — Dose must be adjusted to GFR; taper must account for reduced clearance.
Pregabalin — Dose-adjusted by GFR; haemodialysis removes pregabalin (supplemental dose post-dialysis).
Patients on dialysis may have unpredictable opioid metabolism; specialist renal and pain medicine input is essential.
Hepatic Impairment
Paracetamol — Maximum 2 g/day in chronic liver disease (Child-Pugh A–C).
Opioids — Reduced hepatic clearance of most opioids; avoid codeine (variable metabolism via CYP2D6); prefer short-acting agents with careful dose titration.
Benzodiazepines — Avoid long-acting agents (diazepam, chlordiazepoxide) in cirrhosis; oxazepam and lorazepam are preferred as they undergo Phase II metabolism only.
Assess coagulopathy (INR) before any invasive procedures and consider variceal bleeding risk with NSAID use.
Immunocompromised
Opioids — Chronic opioid use suppresses immune function (reduced NK cell activity, T-cell proliferation). Deprescribing may be particularly beneficial in immunocompromised patients, though evidence is limited.
Drug interactions — Corticosteroid tapering may cause adrenal crisis in patients on concurrent opioids and other CNS depressants. Coordinate tapering schedules carefully.
Patients on immunosuppressive therapy may have altered pain pathways and higher pain sensitivity. Multidisciplinary management is essential.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health Considerations in Deprescribing Analgesics